Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korro Bio, Inc.FREQ · Entity 6388 | Chief Medical Officer | April 20, 2021 | April 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korro Bio, Inc.
Report date April 20, 2021 · Filed April 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 30,000 |
Reported balance
After 2021-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-20 · Grant · Acquired 30,000 · Balance 30,000 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2021 Filed Apr 22, 2021 16:18 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014287 · form4.xml · derivative · entry 1 Hilt Dana Charles · CIK 0001360756 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 16:57 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 70,000 | $0.00 Strike: $35.85 | $0.00 |
DisclosureSEC source: 0001127602-21-001988 · form4.xml · derivative · entry 1 Hilt Dana Charles · CIK 0001360756 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-01-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:22 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $25.05 | $0.00 |
DisclosureSEC source: 0001127602-20-005638 · form4.xml · derivative · entry 1 Hilt Dana Charles · CIK 0001360756 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-11 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.